47 related articles for article (PubMed ID: 25397464)
1. Relationship between innate immunity, soluble markers and metabolic-clinical parameters in HIV+ patients ART treated with HIV-RNA<50 cp/mL.
Dentone C; Fenoglio D; Signori A; Cenderello G; Parodi A; Bozzano F; Guerra M; De Leo P; Bartolacci V; Mantia E; Orofino G; Kalli F; Marras F; Fraccaro P; Giacomini M; Cassola G; Bruzzone B; Ferrea G; Viscoli C; Filaci G; De Maria A; Di Biagio A
J Int AIDS Soc; 2014; 17(4 Suppl 3):19718. PubMed ID: 25397464
[TBL] [Abstract][Full Text] [Related]
2. Circulating interleukin-6 levels correlate with residual HIV viraemia and markers of immune dysfunction in treatment-controlled HIV-infected patients.
Bastard JP; Soulié C; Fellahi S; Haïm-Boukobza S; Simon A; Katlama C; Calvez V; Marcelin AG; Capeau J
Antivir Ther; 2012; 17(5):915-9. PubMed ID: 22436412
[TBL] [Abstract][Full Text] [Related]
3. Visceral leishmaniasis as an independent cause of high immune activation, T-cell senescence, and lack of immune recovery in virologically suppressed HIV-1-coinfected patients.
Casado JL; Abad-Fernández M; Moreno S; Pérez-Elías MJ; Moreno A; Bernardino JI; Vallejo A
HIV Med; 2015 Apr; 16(4):240-8. PubMed ID: 25604328
[TBL] [Abstract][Full Text] [Related]
4. Virologically suppressed HIV patients show activation of NK cells and persistent innate immune activation.
Lichtfuss GF; Cheng WJ; Farsakoglu Y; Paukovics G; Rajasuriar R; Velayudham P; Kramski M; Hearps AC; Cameron PU; Lewin SR; Crowe SM; Jaworowski A
J Immunol; 2012 Aug; 189(3):1491-9. PubMed ID: 22745371
[TBL] [Abstract][Full Text] [Related]
5. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
[TBL] [Abstract][Full Text] [Related]
6. CD8/CD38 activation yields important clinical information of effective antiretroviral therapy: findings from the first year of the CIPRA-SA cohort.
Glencross DK; Janossy G; Coetzee LM; Lawrie D; Scott LE; Sanne I; McIntyre JA; Stevens W
Cytometry B Clin Cytom; 2008; 74 Suppl 1():S131-40. PubMed ID: 18228566
[TBL] [Abstract][Full Text] [Related]
7. Residual viraemia in HIV-1-infected patients with plasma viral load Ostrowski SR; Katzenstein TL; Pedersen BK; Gerstoft J; Ullum H
Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
[TBL] [Abstract][Full Text] [Related]
8. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
Resino S; Bellón JM; Ramos JT; Gonzalez-Rivera M; de José MI; González MI; Gurbindo D; Mellado MJ; Cabrero E; Muñoz-Fernández MA
J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
[TBL] [Abstract][Full Text] [Related]
9. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression.
Serrano-Villar S; Gutiérrez C; Vallejo A; Hernández-Novoa B; Díaz L; Abad Fernández M; Madrid N; Dronda F; Zamora J; Muñoz-Fernández MÁ; Moreno S
J Infect; 2013 Jan; 66(1):57-66. PubMed ID: 23046968
[TBL] [Abstract][Full Text] [Related]
10. Nevirapine use, prolonged antiretroviral therapy and high CD4 nadir values are strongly correlated with undetectable HIV-DNA and -RNA levels and CD4 cell gain.
Sarmati L; Parisi SG; Montano M; Andreis S; Scaggiante R; Galgani A; Viscione M; Maffongelli G; Ricciardi A; Andreoni C; Boros S; Palù G; Andreoni M
J Antimicrob Chemother; 2012 Dec; 67(12):2932-8. PubMed ID: 22915460
[TBL] [Abstract][Full Text] [Related]
11. Close association of CD8+/CD38 bright with HIV-1 replication and complex relationship with CD4+ T-cell count.
Tuaillon E; Al Tabaa Y; Baillat V; Segondy M; Picot MC; Reynes J; Vendrell JP
Cytometry B Clin Cytom; 2009 Jul; 76(4):249-60. PubMed ID: 19072838
[TBL] [Abstract][Full Text] [Related]
12. Influence of antiretroviral therapy on oxidative stress and cardiovascular risk: a prospective cross-sectional study in HIV-infected patients.
Masiá M; Padilla S; Bernal E; Almenar MV; Molina J; Hernández I; Graells ML; Gutiérrez F
Clin Ther; 2007 Jul; 29(7):1448-55. PubMed ID: 17825696
[TBL] [Abstract][Full Text] [Related]
13. The impact of nevirapine- versus protease inhibitor-based regimens on virological markers of HIV-1 persistence during seemingly suppressive ART.
Kiselinova M; Anna M; Malatinkova E; Vervish K; Beloukas A; Messiaen P; Bonczkowski P; Trypsteen W; Callens S; Verhofstede C; De Spiegelaere W; Vandekerckhove L
J Int AIDS Soc; 2014; 17(4 Suppl 3):19823. PubMed ID: 25397567
[TBL] [Abstract][Full Text] [Related]
14. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
Zhang ZN; Shang H; Jiang YJ; Liu J; Dai D; Diao YY; Geng WQ; Jin X; Wang YN
Chin Med J (Engl); 2006 Dec; 119(23):1966-71. PubMed ID: 17199940
[TBL] [Abstract][Full Text] [Related]
15. Immune modulatory effects of cyclooxygenase type 2 inhibitors in HIV patients on combination antiretroviral treatment.
Kvale D; Ormaasen V; Kran AM; Johansson CC; Aukrust P; Aandahl EM; Frøland SS; Taskén K
AIDS; 2006 Apr; 20(6):813-20. PubMed ID: 16549964
[TBL] [Abstract][Full Text] [Related]
16. [T-cell subsets variation during clinical and immunological progression in vertically HIV-infected children].
Resino García S; Bellón Cano JM; Navarro Caspistegui J; Gurbindo Gutiérrez D; León Leal JA; Muñoz-Fernández MA
Medicina (B Aires); 2001; 61(5 Pt 1):557-65. PubMed ID: 11721322
[TBL] [Abstract][Full Text] [Related]
17. Intensification of antiretroviral therapy with raltegravir or addition of hyperimmune bovine colostrum in HIV-infected patients with suboptimal CD4+ T-cell response: a randomized controlled trial.
Byakwaga H; Kelly M; Purcell DF; French MA; Amin J; Lewin SR; Haskelberg H; Kelleher AD; Garsia R; Boyd MA; Cooper DA; Emery S;
J Infect Dis; 2011 Nov; 204(10):1532-40. PubMed ID: 21930607
[TBL] [Abstract][Full Text] [Related]
18. Activation of NK cells is associated with HIV-1 disease progression.
Kuri-Cervantes L; de Oca GS; Avila-Ríos S; Hernández-Juan R; Reyes-Terán G
J Leukoc Biol; 2014 Jul; 96(1):7-16. PubMed ID: 24399837
[TBL] [Abstract][Full Text] [Related]
19. Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels.
Hey-Cunningham WJ; Murray JM; Natarajan V; Amin J; Moore CL; Emery S; Cooper DA; Zaunders J; Kelleher AD; Koelsch KK;
AIDS; 2015 May; 29(8):911-9. PubMed ID: 25730509
[TBL] [Abstract][Full Text] [Related]
20. Changes in levels of T cell subpopulations to monitor the response to antiretroviral therapy among HIV-1-infected patients during two years of HIV-1 replication suppression.
Zhang JC; Zhang HJ; Li Y; Jing D; Liu Q; Zhao K; Liu QQ; Zhuang Y; Kang WZ; Sun YT
Scand J Infect Dis; 2013 May; 45(5):368-77. PubMed ID: 23186319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
